23 September 2019 - There has been continual interest in what the UK’s health technology assessment agency, NICE, has said when it comes to cancer drugs. 

This is not only because of the desire to get access, but also because of high prices. NICE is now 20, and in a move to improve transparency produces a downloadable excel file for both cancer, and non-cancer, Technology Appraisals (TAs).

NICE has done more TAs on non-cancer drugs than cancer drugs from 1999/0 to 2018/19; 488 to 310 TAs.

Read Pharmaphorum article